mRNA-therapeutics have become the most discussed and growing modality in recent years. While COVID vaccine development occurred in record time, critical design and quality attributes must be considered when developing mRNA for other therapeutic applications. This presentation covers the key quality attributes and analytics impacting mRNA performance, including best practices to ensure success. Furthermore, we discuss how our unique PCR-based mRNA CDMO service technology can accelerate mRNA development and manufacturing for our customers.
In this webinar, you will learn:
- How the mRNA-based therapeutics pipeline is rapidly evolving
- About key quality attributes and associated analytics for successful mRNA therapeutic applications
- How our PCR-based technology can accelerate your mRNA development and manufacturing program
Speakers
Julian Mochayedi, Ph.D.
MilliporeSigma
Strategic Marketing Manager for mRNA Solutions
Julian Mochayedi is the strategic marketing manager for mRNA solutions and is responsible for the strategy development and positioning of the mRNA offering based on the acquisition of AmpTec, a leading mRNA CDMO. He holds an M.Sc. in bioprocess development and a Ph.D. in translational immunology from the University of Heidelberg with expertise in the area of in vivo gene editing.
Christof Trabszo, Ph.D.
MilliporeSigma
Head of Quality Control
Christof is head of quality control at the mRNA Center of Excellence in Hamburg, and he is responsible for the development, coordination, and implementation of state-of-the-art mRNA analytics. Before dedicating himself to the mRNA business, he gained experience in several positions within the pharmaceutical industry for traditional vaccine manufacturing. Christof holds a Ph.D. in cellular biochemistry from the University of Bielefeld.
To continue reading please sign in or create an account.
Don't Have An Account?